SCHEMBL27216970

SCHEMBL27216970

Cn1cnc(Br)c1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD3 Q9BZ95 1/20 0.54
KDR P35968 3/20 0.42
KMT2A Q03164 1/20 0.39
HPGDS O60760 1/20 0.39
DPP4 P27487 2/20 0.37
DPP8 Q6V1X1 1/20 0.37
FLT1 P17948 2/20 0.37
TEK Q02763 2/20 0.37
MAPK14 Q16539 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
TSHR P16473 1/20 0.36
LDLR P01130 1/20 0.36
PCSK9 Q8NBP7 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
NLRP3 Q96P20 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15875369 0.81 KDM5A (0.45) NSD3KMT2AMAPK14NPC1RAB9A
SCHEMBL31627219 0.80 CYP2A6 (0.49) NSD3TSHRCYP1A2CYP3A4CYP2D6
SCHEMBL12926032 0.78 NSD3 (0.56) NSD3KDRKMT2AHPGDSDPP4
SCHEMBL1009513 0.78 NSD3 (0.83) NSD3KDRFLT1TEKMAPK14
SCHEMBL17928542 0.76 NSD3 (0.54) NSD3KDRHPGDSDPP4DPP8
SCHEMBL29874438 0.76 NSD3 (0.80) NSD3KDRFLT1TEKMAPK14
SCHEMBL18721829 0.76 NSD3 (0.54) NSD3KDRKMT2AHPGDSDPP4
SCHEMBL27217114 0.76 HDAC3 (0.47) NSD3TEKCA1CA2TSHR
SCHEMBL27217160 0.72 NSD3 (0.54) NSD3KDRHPGDSDPP4DPP8
SCHEMBL27217169 0.72 TLR7 (0.45) TEKMAPK14PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 EP disclosed
WO-2025128834-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2025-06-19 WO disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS CKS1B, CKS2, MARK1 NSD3 1762/4885KDR 2838/4885KMT2A 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.